Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Pfizer's COVID-19 vaccine continues to show strong protection against serious illness and hospitalization after 6 months, but overall protection against the virus appears to wane after a half a year, according to a new study.
The July 28 preprint report of the study, which has not been peer reviewed, suggests a gradual "declining trend in vaccine efficacy" over 6 months after a two-dose regimen of the Pfizer vaccine. The study included more than 45,000 people worldwide.
The study found that overall effectiveness fell from 96% to 84%.
A third booster dose of the Pfizer vaccine increases neutralizing antibody levels against the Delta variant by more than five times compared to levels after a second dose in people aged 18 to 55 years, new data from Pfizer show.
The immune response to the third dose appears even more robust ― more than 11 times higher than the response to second shot ― among people aged 65 to 85 years.
The July 28 preprint report of the study, which has not been peer reviewed, suggests a gradual "declining trend in vaccine efficacy" over 6 months after a two-dose regimen of the Pfizer vaccine. The study included more than 45,000 people worldwide.
The study found that overall effectiveness fell from 96% to 84%.
A third booster dose of the Pfizer vaccine increases neutralizing antibody levels against the Delta variant by more than five times compared to levels after a second dose in people aged 18 to 55 years, new data from Pfizer show.
The immune response to the third dose appears even more robust ― more than 11 times higher than the response to second shot ― among people aged 65 to 85 years.
Pfizer Vaccine Protection Wanes After 6 Months: Study
Following reports that antibody levels can wane after a second dose of the Pfizer mRNA come more encouraging data regarding a third dose.
www.medscape.com